000282929 001__ 282929
000282929 005__ 20251218141446.0
000282929 037__ $$aDZNE-2025-01390
000282929 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000282929 245__ $$aDataset: A proteomics resource for human iPSC-derived endothelial cells (iEC), smooth muscle cells (iSMC), pericytes (iPC) and astrocytes (iAS) in comparison to human primary cells - technical and biological replicates (Project PXD066414)
000282929 260__ $$bPRoteomics IDEntifications Database$$c2025
000282929 3367_ $$2BibTeX$$aMISC
000282929 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1766063665_31262
000282929 3367_ $$026$$2EndNote$$aChart or Table
000282929 3367_ $$2DataCite$$aDataset
000282929 3367_ $$2ORCID$$aDATA_SET
000282929 3367_ $$2DINI$$aResearchData
000282929 520__ $$aIntegrity of the blood-brain barrier (BBB) is critical for brain homeostasis, and its malfunction contributes to neurovascular and neurodegenerative disorders. So far, mechanistic studies on BBB function have been mostly conducted in rodent and non-physiological in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human iPSC-derived, microfluidic 3D BBB model consisting of endothelial cells (EC), mural cells, and astrocytes. Our model expresses typical cell fate markers, forms a barrier in vessel-like tubes, and enables perfusion, including with human blood. We optimized iPSC differentiations and validated cellular fates by comparison to published datasets and extensive benchmarking vs. primary cells with proteomic profiles provided in an online database (https://dbNeuroVasP.isd-muc.de).
000282929 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000282929 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000282929 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD066414
000282929 909CO $$ooai:pub.dzne.de:282929$$pVDB
000282929 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000282929 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000282929 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000282929 9141_ $$y2025
000282929 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000282929 980__ $$adataset
000282929 980__ $$aVDB
000282929 980__ $$aI:(DE-2719)1110006
000282929 980__ $$aUNRESTRICTED